 Rockwell Medical Inc NASDAQ: RMTI has announced the publication of results in the Journal of Bioequivalence Bioavailability from a study evaluating the co-administration of intravenous IV Ferric Pyrophosphate Citrate FPC, Triferic with unfractionated heparin UFH as an admixture. The study demonstrated no clinically relevant drug-drug interaction DDI between FPC and UFH on the effects of UFH nor on the ability of FPC to deliver bioavailable iron when these agents are co-administered as a single admixture via an HD-machine syringe pump. 